| Item type |
学内発行雑誌 / Departmental Bulletin Paper(1) |
| 公開日 |
2018-09-05 |
| タイトル |
|
|
タイトル |
Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ |
departmental bulletin paper |
| 著者 |
MANABE, Ryo
ANDO, Koichi
KUSUMOTO, Sojiro
TANAKA, Akihiko
YAMAOKA, Toshimitsu
OHMORI, Tohru
OHNISHI, Tsukasa
SAGARA, Hironori
|
| 書誌情報 |
The Showa University journal of medical sciences
巻 30,
号 2,
p. 309-315,
発行日 2018-06
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
The safety and efficacy profiles of alectinib versus crizotinib for patients with previously untreated anaplastic lymphoma kinase （ALK）-positive advanced non-small cell lung cancer still remains to be elucidated. We compared the overall efficacies of alectinib and crizotinib for previously untreated ALK-positive advanced non-small cell lung cancer through a meta-analysis of randomized controlled trials. The primary outcome was progression-free survival （PFS）. Pooled estimates were calculated as hazard ratios with 95％ confidence intervals. Two studies on alectinib met the inclusion criteria for this meta-analysis. The hazard ratio （95％ confidence interval） of alectinib for PFS, relative to crizotinib, was 0.41 （0.28-0.60）, demonstrating a superior overall efficacy of alectinib over crizotinib, in terms of PFS. |
| DOI |
|
|
|
関連識別子 |
10.15369/sujms.30.309 |
| 出版者 |
|
|
出版者 |
Showa University Society |
| ISSN |
|
|
収録物識別子 |
0915-6380 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
S30_309.pdf (427.1 kB)
